Friday 06/February/2026 – 10:52 AM
revealed study Recent scientific studies have reported promising results that may represent an important step in slowing the progression of Alzheimer’s disease, by combining low doses of a cannabis compound with a widely used anti-inflammatory, according to what was published in foxnews.
Study opens new door to Alzheimer’s prevention by using a cannabis compound with common painkillers
According to the research, conducted by a team at the University of Texas at San Antonio and published in the Journal of Aging and Neurological Diseases, THC, when used alone, has previously shown neuroprotective properties, but at the same time has been associated with negative effects on memory and learning.
What is new in this study is that the researchers found that combining THC with the drug celecoxib, an analgesic and anti-inflammatory drug that inhibits the COX-2 enzyme, may achieve noticeable cognitive benefits without stimulating the neuroinflammation associated with the use of the compound alone.
The experiments were conducted on mice that were given the combination treatment daily for 30 days before symptoms of memory loss appeared, with the aim of measuring the ability of the treatment to prevent or delay cognitive decline.
The results showed a clear improvement in cognition, learning, and memory, along with a significant decrease in indicators of inflammation within the brain, and a decline in signs associated with neuronal damage resulting from Alzheimer’s.
The researchers noted that using THC alone achieved some positive results, but in return it increased the activity of inflammatory enzymes associated with poor cognitive function, which was not seen when used in conjunction with celecoxib.
The main researcher in the study explained that the main problem in neurological treatments is not only related to biological changes, but rather to actually improving behavior and cognitive abilities, which is what combination therapy succeeded in doing better compared to using THC alone.
He added that THC may lead to an unexpected increase in the COX-2 enzyme inside the brain, which explains the decline in memory in some cases, stressing that combining it with an inhibitor of this enzyme may be the key to reducing side effects.
The fact that both THC and celecoxib have been approved by the US Food and Drug Administration for human use is encouraging, as it may facilitate the transition to human clinical trials in the near future.
Neurosurgeons believe that these results reinforce the hypothesis that chronic inflammation within the brain plays a pivotal role in the development of Alzheimer’s, and that reducing this inflammation may limit the accumulation of beta-amyloid plaques associated with the disease.
